We welcome those interested in NIDA’s HIV research. Watch this space for messages from the ARP scientific leadership team on interesting new findings in the field as well as funding opportunities from NIDA.
- 2021 Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research. Congratulations to Drs Linda Chang and Alex K. Shalek, recipients of the
- Ending the HIV Epidemic: A Plan for America (EHE) initiative.
NIDA is joining NIAID in three new RO1 funding opportunities (with clinical trials optional) linked to the pillars of the
- Epidemiology to End the HIV Epidemic
Applications should address the RESPOND pillar of the EHE initiative. We are seeking research to help us better understand HIV susceptibility and ongoing transmission in the United States using local and population-level epidemiology in collaboration with implementing partners.
- Prevention Strategies to End the HIV Epidemic
Research funded under this FOA will seek to reduce HIV incidence by supporting the goals of the DIAGNOSE and PREVENT pillars of the EHE initiative. We are looking for creative, multidisciplinary approaches to meet the needs of specific populations and localities. This opportunity will support projects to improve use of evidence-based HIV prevention interventions among populations in priority areas identified as highly impacted by HIV.
- Multidisciplinary Treatment Approaches to End the HIV Epidemic
Proposals should address the DIAGNOSE and TREAT pillars of the EHE initiative by exploring concepts for improved healthcare engagement that result in rapid and sustained viral suppression and improved outcomes for people with HIV. We are looking for methodologies that utilize implementation science to develop, implement, and evaluate creative, multidisciplinary approaches to healthcare delivery that more effectively engage and retain individuals in HIV care and treatment so that they achieve durable viral suppression.
- Epidemiology to End the HIV Epidemic
- how CRISPR diagnostics can augment gold-standard PCR-based testing for COVID-19 detection. This exciting research developed a way to use CRISPR-Cas13a to detect and quantify SARS-CoV-2 RNA from patient samples without the need for a pre-amplification step, and demonstrated how the signal can be efficiently detected with a portable, mobile phone-based device. We’d like to congratulate NIDA’s Avant Garde Awardee Melanie Ott and her colleagues for their just published manuscript in CELL on
- Notice of Special Interest (NOSI) for Multi-Level HIV Prevention Interventions: NIDA, along with the National Institutes on Minority Health and Health Disparities (NIMHD) and Mental Health (NIMH) are offering funding opportunities to test the effectiveness of multi-level interventions to prevent HIV in high-risk health disparity populations in one or more geographic hotspots, including men who have sex with men (MSM), and/or minority transgender women, as these populations account for over half of new infections. Projects are generally expected to be clinical trials promoting PrEP use, condom use, and HIV testing in HIV-negative individuals. NIDA is especially interested in supporting research under this NOSI involving people who use drugs including members of key populations among whom drug use is a common HIV acquisition risk. Areas of special interest to NIDA are multi-level interventions that incorporate substance use treatment, harm reduction or other settings that commonly provide substance use services. Projects should use existing evidence-based HIV-prevention interventions or practices, either alone or in combination with new intervention elements. NIDA is looking for structural interventions to reduce HIV acquisition conducted in partnership with clinicians and service providers responsible for delivering HIV prevention services or programs at the local, state, or regional level.
- Notice of Special Interest (NOSI) Promoting Viral Suppression: NIDA, NIMHD and NIMH are also offering new funding opportunities that test interventions to promote ART initiation, ART adherence, and suppressed viral load for typically underserved people living with HIV in one or more hotspots. NIDA is interested in testing of interventions that directly engage sexual and/or injecting partners in ART adherence and HIV transmission prevention, as well as clinic-level intervention components to enhance cultural competency and reduce health-care related stigma and discrimination toward people living with HIV who are racial/ethnic or sexual and gender minorities. Proposals should include engagement of high risk populations and related subgroups, and should encourage collaboration with diverse local stakeholders. Projects that develop and test interventions to minimize delays in initiating or re-initiating ART services for people who use drugs are encouraged, as are proposals that incorporate cost-effectiveness analysis.
- Please note the just released funding opportunity from our colleagues at the National Institute of Mental Health on research applications to optimize health communication strategies that advance HIV prevention, diagnosis, treatment and cure efforts, as well as research on communication, dissemination and implementation factors that are required for successful public understanding and acceptance of HIV-related interventions. Proposals are especially encouraged related to digital technologies, health disparities, as well as knowledge management and learning.
- virtual Symposium honoring six recipients of the Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research. Symposium registration is now online. The NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research supports individual scientists of exceptional creativity at all career levels who propose high-impact research that will open new areas of HIV research and/or lead to new avenues for prevention and treatment of HIV among people who use drugs. Learn more about NIDA’s HIV/AIDS Avant Garde Award Program: On April 27 from 1 - 4:30 pm, the NIDA AIDS Research Program will be holding a
- video from our January Symposium featuring previous HIV/AIDS Avenir Award recipients. Learn more about their innovative research as you prepare your own proposals. Note that applications are accepted in the summer and do not require preliminary data. The Avenir award provides up to $375,000 per year for 4 years to support cutting-edge and potentially transformative projects. Early stage and new investigators: We have posted the
- findings underscore that expanding public health insurance is one tool that can help curb the HIV epidemic. NIH-funded research demonstrates that Medicaid expansions were associated with increases in the percentage of people living with HIV who are aware of their status and pre-exposure prophylaxis use, suggesting that access to health care increases knowledge and implementation of prevention and treatment strategies.
SAMHSA’s new publication Prevention and Treatment of HIV Among People Living with Substance Use and/or Mental Disorders addresses the co-occurrence of HIV and substance use disorder and/or mental illness, and reviews effective programs and practices to prevent HIV and, for those with HIV, to increase linkage and retention to care in order to improve health outcomes.
- published new findings exploring women’s interest in long-acting injectable antiretroviral therapy. Most women with a history of taking injectable medication would prefer the longer acting treatment, but those who have frequent medication-related injections and history of injection drug use might not, underscoring the need for further research to address patient-centered concerns related to injectable medication. A multi-state research team has
Findings from two studies this month relate to the use of methamphetamine, a drug known to be an important factor in the transmission of HIV by increasing sexual urges and decreasing behaviors that prevent HIV and other sexually transmitted infections.
- A double-blind, placebo-controlled Phase III clinical trial demonstrated that a combination of two existing medications, injectable naltrexone and oral bupropion, was safe and effective in treating adults with moderate or severe methamphetamine use disorder. Published in The New England Journal of Medicine, the research was done at multiple sites within NIDA’s Clinical Trials Network. The investigators found that the effectiveness of the combination is similar to the effectiveness of analgesics for treating pain and most medical treatments for mental health disorders. You can read more about this exciting development in Dr. Volkow’s latest blog.
- Highlighting the growing need for this treatment, an analysis by NIDA scientists over an eight year period ending in 2018 showed a five-fold increase of methamphetamine overdose deaths among people ages 25-54, with the biggest increase among American Indians and Alaska Natives. This important finding underscores the urgency of continued research into targeted and culturally tailored treatments for stimulant use disorder, which currently has no FDA-approved medication.
- Wednesday, January 27th for a virtual symposium featuring previous award recipients to learn about the innovative research funded through this program. Register for the symposium here. Note that applications are accepted in the summer and do not require preliminary data. Early stage and new investigators: It’s time to start thinking about applying for the HIV/AIDS Avenir award, which provides up to $375,000 per year for 4 years to support cutting-edge and potentially transformative projects. Join us
- elite controllers was selected as one of nine runners up for Science magazine’s Breakthrough of the Year.
Other research published this year includes unprecedented findings that higher viral reservoirs might exist in the central nervous system of combined antiretroviral therapy (cART)-treated subjects, underscoring the importance of substance use status in developing targeted HIV therapies. In 2020, we also learned more about the link between rising stimulant use and HIV transmission, and how co-occurring methamphetamine use and HIV compounds the risk for contracting COVID-19.
In addition, we celebrated progress through our sponsorship of a supplement to the Journal of Neuroimmune Pharmacology, Unraveling neuroHIV in the Presence of Substance Use Disorders, with ten NIDA-funded HIV-related scientific manuscripts. We saw a mid-year blog from NIDA Director Nora Volkow looking at the intersection of HIV with substance use disorders amidst the COVID-19 pandemic, and on December 1st, NIDA honored World AIDS Day by announcing new infographic timelines highlighting the program’s historical impact since its inception in 2004. Finally, to bring ARP-stimulated research to the public more quickly, in 2020 we began posting online an ongoing selection of science highlights illuminating important advances in NIDA-funded HIV research.
The ARP team wishes all a Happy New Year filled with hope, and wants to give thanks to program staff and grantees who continue to pursue innovative science aimed at reducing the global burden of HIV. We’d especially like to mention staffer Andrea Czajkowski, who keeps things running day after day at NIDA’s AIDS Research Program.
- The year 2020 was difficult indeed, but despite the challenges of COVID-19, NIDA’s AIDS Research Program moved forward with some impressive advances. At year’s end we learned that the NIDA-funded research on
- "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity” announcement is a terrific funding opportunity for nonprofits, small businesses, local governments and higher education institutions (particularly those serving diverse student populations), with interest in projects that have the potential to improve the lives of those most at risk for HIV. Please note that the PAR-19-343 will now accept AIDS and AIDS-related applications, with a deadline extended to January 8, 2020. This
- NIDA funded study examining the challenges of managing pain for people living with HIV. This can be important for people who use or have a history of misusing drugs, especially opioids, and now that safe and effective HIV treatment allows people living with HIV to lead long, productive lives.
We’d like to bring to your attention a
- Painful Subjects: Treating Chronic Pain among People Living with HIV in the Age of Opioid Risk. Carroll JJ, Lira MC, Lunze K, Colasanti JA, Del Rio C, Samet JH. Med Anthropol Q. 2020 Nov 5. doi: 10.1111/maq.12618. Online ahead of print. PMID: 33152133
- high impact research findings, and the other identifies key policy and outreach milestones. These timelines not only reveal a history of program accomplishments but also forecast future achievements in research.
To celebrate World AIDS Day, NIDA has created two graphic timelines to honor the research and policy highlights that have advanced our scientific knowledge of the intersection of substance use and HIV transmission since NIDA’s AIDS Research Program was formed in 2004. One timeline identifies some of our
- We also want to bring to your attention some new interesting research findings that examine the biological mechanisms of elite controllers—the tiny fraction of HIV patients who can suppress the virus without medication.
We are pleased to highlight two new NIDA/NIMHD co-funded opportunities:
- First - we are seeking innovative projects that directly engage at risk populations, including structural interventions that can improve access to substance use prevention, treatment and harm reduction initiatives. We are especially interested in interventions that will include collaborations with diverse local stakeholders and address comorbidities such as intimate partner violence, marginal housing or serious mental disorders. See Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection
- We are also seeking cost-effective care innovations for people who are HIV positive or suffer from substance use disorders, with a focus on harm reduction service settings in multiple geographic hotspots. Interventions could highlight novel approaches to PrEP delivery and/or clinic-level culturally competent components to reduce health care related stigma with a focus on racial/ethnic minorities, and/or sexual and gender minorities. See Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care.
- new NIH Stephen I. Katz Early Stage Investigator Research Project Grant funding opportunities, which support innovative projects that represent a change in research direction for early stage investigators. Take note of the
- findings that demonstrate the superiority of long-acting injectable Cabotegravir to daily oral FTC/TDF for HIV prevention among certain populations of women. This remarkable advance signals an area of important research for us to answer questions about the acceptability, feasibility, and implementation of this potential tool into the care of women who use drugs. Congratulations to the HTPN 084 study scientific team for their new